Abcam, ab249925, Anti-MIF antibody [EPR12462] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal MIF antibody. Carrier free. Suitable for IP, WB, ICC/IF and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR12462,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:ICC/IF, WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249925 is the carrier-free version of
ab176565
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please
contact us
for more information.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Macrophage migration inhibitory factor (MIF) also known as glycosylation-inhibiting factor is a protein with a molecular mass of approximately 12.5 kDa. It plays a mechanistic role as a cytokine that regulates immune responses specifically influencing macrophage behavior. MIF expresses in various cell types including immune and epithelial cells. It gets secreted by activated lymphocytes and macrophages pointing to its involvement in the inflammatory process.
Biological function summary
MIF acts as an upstream regulator of innate immunity and exerts broad influence on cytokine release. MIF elevates pro-inflammatory cytokines like TNF-alpha and IL-1beta promoting an immune response. It does not typically form part of a complex but interacts with cell surface receptors like CD74 triggering intracellular signaling pathways. These interactions illustrate MIF as a regulator of immune cell recruitment and activation.
Pathways
MIF participates in the glucocorticoid receptor regulatory pathway and MAP kinase pathway. It shows interaction with JNK and ERK1/2 proteins which further map into important cellular reactions like stress response and cell proliferation. By integrating into these pathways MIF influences cell survival proliferation and inflammatory cascades emphasizing its role in immune regulation.
MIF links to inflammatory diseases such as rheumatoid arthritis and sepsis. It influences disease progression by interacting with proteins like TNF-alpha and IL-6 contributing to inflammatory damage. Elevated MIF levels often correlate with disease severity in rheumatoid arthritis acting as a potential target for therapy. Furthermore sepsis demonstrates a similar pattern where MIF modulation can impact patient outcomes underlining its relevance in clinical investigations.